Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 5,921 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mouth Disease Clear all
Not yet recruiting Phase 2 Interventional

SCI-110 in the Treatment of Tourette Syndrome

NCT05126888
View directory record Official record
Conditions
Tourette Syndrome
Interventions
SCI-110, Placebo
Drug · Other
Lead sponsor
Neurothera Labs Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional

Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx

NCT00064103
View directory record Official record
Conditions
Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Stage 0 Lip and Oral Cavity Cancer, Stage 0 Oropharyngeal Cancer, Tongue Cancer
Interventions
Ad5CMV-p53 gene, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis

NCT00071461
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
bosentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 31, 2026, 5:33 PM EDT
Terminated Phase 3 Interventional Results available

Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy

NCT02539342
View directory record Official record
Conditions
Oral Mucositis
Interventions
Caphosol, Biotene
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 31, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Apremilast in the Treatment of Moderate to Severe Acne

NCT01074502
View directory record Official record
Conditions
Acne
Interventions
apremilast
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available

Comparing Five Oral Analgesics for Treatment of Acute Pain in the Emergency Department (ED)

NCT03173456
View directory record Official record
Conditions
Musculoskeletal Pain
Interventions
oxycodone/APAP, hydrocodone/APAP, codeine/APAP, 400 ibuprofen/APAP, 800 ibuprofen/APAP
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 64 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

NCT02291029
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, CFZ533 active - Cohort 2, CFZ533 placebo - Cohort 2, CFZ533 active - Cohort 3
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

NCT02273739
View directory record Official record
Conditions
Solid Tumor, Glioma, Angioimmunoblastic T-cell Lymphoma, Intrahepatic Cholangiocarcinoma, Chondrosarcoma
Interventions
Enasidenib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions.

NCT03509675
View directory record Official record
Conditions
Oral Lichen Planus, Oral Lichenoid Mucositis, Oral Lichenoid Reaction
Interventions
Ibuprofen suspension 5mg/100ml, Placebos
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available

Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus

NCT02496000
View directory record Official record
Conditions
Diabetes Type 2
Interventions
ORMD-0801, Placebo Comparator
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
20 Years to 75 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 31, 2026, 5:33 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Study Evaluating Oral-Health-Related Quality of Life and Treatment Patterns Among Dentin Hypersensitivity Sufferers

NCT07337109
View directory record Official record
Conditions
Dentin Hypersensitivity
Interventions
Not listed
Lead sponsor
HALEON
Industry
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

NCT02738151
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin glargine, 300U/mL, Insulin degludec, 100 U/mL, Non-insulin anti-diabetic treatment
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
929 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
74
States / cities
Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available

Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

NCT03015402
View directory record Official record
Conditions
Pulmonary Hypertension Secondary, Heart Failure
Interventions
Sodium Nitrite, Placebo Oral Capsule
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment

NCT04814602
View directory record Official record
Conditions
Cirrhosis, Liver
Interventions
Proglumide
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 2 Interventional Results available

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

NCT02152137
View directory record Official record
Conditions
Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer
Interventions
efatutazone, paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
253
States / cities
Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 168 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment of Periodontitis With Er:YAG Laser

NCT03628872
View directory record Official record
Conditions
Generalized Moderate Chronic Periodontitis, Generalized Severe Chronic Periodontitis, Periodontal Diseases
Interventions
Scaling and root planing, Er:YAG Laser, Hand instruments
Procedure · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 1 Interventional

Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors

NCT00978081
View directory record Official record
Conditions
Head and Neck Cancer, Precancerous Condition
Interventions
aminolevulinic acid hydrochloride
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants

NCT00000944
View directory record Official record
Conditions
HIV Infections, Pregnancy
Interventions
Indinavir sulfate, Lamivudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2003
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older

NCT02058563
View directory record Official record
Conditions
Rubella, Mumps, Measles
Interventions
Priorix®, Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
7 Years and older
Enrollment
996 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
10
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Not applicable Interventional

Evaluation of Geistlich Fibro-Gide® + CAF in Comparison to CTG + CAF for the Treatment of Recession Defects at 6 Months

NCT04260152
View directory record Official record
Conditions
Gingival Recession
Interventions
Geistlich Fibro-Gide, Connective Tissue Graft (CTG
Device · Procedure
Lead sponsor
Geistlich Pharma AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Fenton, Michigan • Houston, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Not applicable Interventional Results available

A Study to Determine the Effects of Adding an Experimental Device With Mouthrinse to Oral Care Regimen

NCT01419626
View directory record Official record
Conditions
Gingivitis
Interventions
Interdental cleaning device with water, Interdental cleaning device with essential-oil mouthrinse
Device
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 31, 2026, 5:33 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Comparing Mouth Rinses (and Chewing Gum) in Regard to Streptococcus Mutans Reduction

NCT02598778
View directory record Official record
Conditions
Dental Caries
Interventions
Chlorhexidine gluconate (0.12%), Sodium Fluoride (0.05%), Paraffin wax chewing gum (sugar-free), Deionized water
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
6 Years to 12 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 31, 2026, 5:33 PM EDT
Recruiting Phase 1 Interventional

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NCT06191978
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
ASTX727, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 31, 2026, 5:33 PM EDT
Completed Phase 1 Interventional Results available

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

NCT01286987
View directory record Official record
Conditions
Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 31, 2026, 5:33 PM EDT